GALAPAGOS news, videos and press releases
For more news please use our advanced search feature.
GALAPAGOS - More news...
GALAPAGOS - More news...
- Galapagos to Present Results of Pioneering Innovation in Cancer Cell Therapy at ASH 2024
- Galapagos Reports Third Quarter 2024 Financial Results and Provides Business Update
- Galapagos welcomes Oleg Nodelman to its Board of Directors to support strategic growth
- Galapagos receives transparency notification from EcoR1 Capital
- Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune’s TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indications
- Galapagos reports first quarter 2024 financial results
- Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024
- Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
- Galapagos establishes strategic collaboration with BridGene Biosciences to expand small molecule drug discovery in oncology
- Galapagos to Host KOL Event on December 10, 2023, at 11:00 AM PST to discuss new data presented at ASH 2023
- Galapagos reports third quarter 2023 results and releases new encouraging data from CAR-T studies for presentation at ASH 2023
- Galapagos concludes strategic evaluation and signs letter of intent to transfer Jyseleca® business to Alfasigma
- Galapagos appoints Simon Sturge to its Board of Directors
- Galapagos announces first half-year 2023 financial results
- Galapagos to showcase CAR-T point-of-care manufacturing and initial Phase 1/2 CLL data with CD19 CAR-T candidate, GLPG5201, at the EHA 2023 congress
- Galapagos demonstrates commitment to immunology with new data in rheumatoid arthritis at EULAR 2023
- Galapagos creates new subscription right plans
- Galapagos announces first quarter 2023 financial results
- Galapagos initiates Phase 3 program with filgotinib in patients with active axial spondyloarthritis
- Galapagos to present new data from long-term extension study of filgotinib in ulcerative colitis at annual ECCO congress 2023
- Galapagos announces topline results from Phase 3 DIVERSITY trial of filgotinib in Crohn’s disease
- Galapagos receives transparency notification from FMR LLC
- Galapagos announces changes to Executive Committee
- Galapagos to present encouraging initial data from FILOSOPHY real-world arthritis study at ACR Convergence 2022
- Galapagos announces strategy to accelerate innovation and reports strong third quarter 2022 results
- Galapagos provides further insights into the treatment of ulcerative colitis at the upcoming United European Gastroenterology (UEG) Week 2022 congress
- Galapagos receives positive CHMP opinion for Jyseleca® European label update based on testicular function safety data from MANTA/RAy studies
- Galapagos increases share capital through subscription right exercises
- Galapagos to present at upcoming investor conferences
- Galapagos receives transparency notification from FMR LLC
